High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion with Seizure Presentation

Clinical Neuropharmacology

Volumn 38, Issue 4, 2015, Pages 154-155

  Lee, Yen Feng ^a   Tsai, Chia Kuang ^a,b   Liang, Chih Sung ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

high dose; risperidone; seizures; syndrome of inappropriate antidiuretic hormone secretion

Indexed keywords

BIPERIDEN; FLUPENTIXOL; POTASSIUM; RISPERIDONE; SODIUM; SODIUM CHLORIDE; ZOLPIDEM;

ADULT; AGGRESSION; ARTICLE; CASE REPORT; CONFUSION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EEG ABNORMALITY; EPILEPTIC DISCHARGE; FEMALE; FLUID INTAKE; FOLLOW UP; HEBEPHRENIA; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LABORATORY TEST; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SCHIZOPHRENIA; SCREENING; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; TONIC CLONIC SEIZURE; UNCONSCIOUSNESS; URINE OSMOLALITY; CHEMICALLY INDUCED; DOSE RESPONSE; SEIZURE;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INAPPROPRIATE ADH SYNDROME; RISPERIDONE; SCHIZOPHRENIA; SEIZURES;

EID: 84938379472     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000095     Document Type: Article

References (15)

1. Ellison DH, Berl T,. The syndrome of inappropriate antidiuresis. N EnglJ Med 2007; 356: 2064-2072.
2. 2 antagonistic properties. Clin Neuropharmacol 1992; 15 (Suppl 1 Pt A): 180A-181A.
3. Rattehalli RD, Jayaram MB, Smith M,. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev 2010;(1): CD006918.
4. Miodownik C, Lerner V,. Risperidone in the treatment of psychotic depression. Clin Neuropharmacol 2000; 23: 335-357.
5. Bishop JR, Pavuluri MN,. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatr Dis Treat 2008; 4: 55-68.
6. Kim JH, Kim MJ,. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clin Neuropharmacol 2009; 32: 250-253.
7. Naranjo CA, Busto U, Sellers EM, A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
8. The use of the WHO-UMC system for standardized case causality assessment. Available at: http://www.who-umc.org/Graphics/24734.pdf. Accessed February 12, 2015.
9. Albers HE, Karom M, Smith D,. Serotonin and vasopressin interact in the hypothalamus to control communicative behavior. Neuroreport 2002; 13: 931-933.
10. de Leon J, Verghese C, Stanilla JK, Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option? Neuropsychopharmacology 1995; 12: 133-138.
11. Knauer CS, Campbell JE, Galvan B, Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur J Pharmacol 2008; 591: 136-141.
12. 2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 2012; 341: 81-89.
13. Gazdag G, Barna I, Iványi Z, The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. Ideggyogy Sz 2004; 57: 385-390.
14. Page CB, Calver LA, Isbister GK,. Risperidone overdose causes extrapyramidal effects but not cardiac toxicity. J Clin Psychopharmacol 2010; 30: 387-390.
15. Liamis G, Milionis H, Elisaf M,. A review of drug-induced hyponatremia. Am J Kidney Dis 2008; 52: 144-153.